Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Aponermin on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Aponermin is a first-of-its-kind cancer medicine for multiple myeloma that keeps coming back. It was developed in China by Wuhan Hiteck Biological Pharma, together with Beijing Sunbio Biotech, and is sold there as 沙艾特®. It is given as a drip alongside two familiar tablets, thalidomide and dexamethasone.
China's National Medical Products Administration (NMPA) approved it in November 2023 for adults with:
It is a prescription blood cancer medicine and should only be used under a haematologist or oncologist.
Our bodies have a natural signal, called TRAIL, that tells damaged cells to self-destruct. Aponermin is a re-engineered, more stable version of that signal, made by bacteria in the lab. It locks on to two "death receptors" on myeloma cells, DR4 and DR5, and switches on the cell's own shutdown process. It is the first approved medicine anywhere that works through these receptors, so it attacks the cancer in a different way from proteasome inhibitors, IMiDs or antibodies.
The phase 3 CPT-MM301 trial, published in BMC Cancer in 2023, included 417 people whose myeloma had come back after at least two treatments. Adding aponermin to thalidomide and dexamethasone nearly doubled the time before the disease got worse (median 5.5 vs 3.1 months). People also lived longer, a median of 22.4 months against 16.4 months in the updated analysis, and more than twice as many responded to treatment (30.4% vs 13.7%).
In the trial, each 28-day cycle looked like this:
Each vial holds 100 mg of powder, which is dissolved and added to a 250 mL drip that runs for about 90 minutes. As an example, a 60 kg patient needs 600 mg a day, or six vials, on each of the five dosing days. Your haematologist sets the exact plan.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Liver enzymes: the main side effect is a rise in liver enzymes. ALT went up in about half of patients (52.5%) and AST in 51.1%, though most rises were mild and short-lived. Severe (grade 3–4) rises happened in 9.4% (ALT) and 12.0% (AST). Liver tests are checked during each cycle, and the dose can be lowered or paused. In the trial, fewer than 3% had to change or stop treatment because of the liver, and no liver failure was reported.
Overall: serious side effects occurred in 40.6% of patients on aponermin and 37.4% on placebo. 8.7% stopped because of side effects, compared with 7.2%. Safety in pregnancy, breastfeeding and children has not been established.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The injection can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. For other options in relapsed myeloma, see our pages on Talvey and Xpovio.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The freeze-dried vials must be kept at 2°C to 8°C and away from light, so they travel under temperature-controlled shipping all the way to the hospital. Because each cycle needs five days of doses, we plan quantities cycle by cycle. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the treating hospital on a valid specialist's prescription.
Major haematology centres here treat myeloma patients from across North India, and our New Delhi dispatch point keeps the cold-chain journey short.
Vials are delivered straight to the hospital pharmacy in time for day 1 of each cycle.
Haematologists in Bangalore can request the medicine for a named patient, with the quote shared before anything is ordered.
A long-standing referral hub for blood cancers in South India, with experience handling refrigerated imported biologics.
We plan deliveries around the five-day dosing window so each cycle starts on time.
Shipments to Kolkata and the eastern states are routed to stay within 2°C to 8°C throughout.
Patients in Pune can use the same documented import route, with updates at each stage.
The treating haematologist can send us the prescription and treatment history to begin the import.
Patients treated at hospitals in Vellore can have each cycle's supply delivered directly to the hospital.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the treating hospital.
We coordinate cold-chain delivery to public and private cancer hospitals across Uttar Pradesh.
Patients across Kerala can receive the medicine at their hospital in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 16 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
